Xue Liu

1.2k citations
37 papers · 800 indexed · 1 hit paper · h-index 15
Topics
Extracellular vesicles in disease (11 papers)MicroRNA in disease regulation (8 papers)interferon and immune responses (3 papers)

In The Last Decade

Xue Liu

35 papers receiving 796 citations

Hit Papers

Neutrophil Membrane‐Camouflaged Polyprodrug Nanomedicine ...2024202620252024204060

Peers

Xue Liu
Comparison fields: 5 of 109
  • Molecular Biology 461
  • Cancer Research 217
  • Oncology 164
  • Immunology 131
  • Biomedical Engineering 97
Replace Myung K. Shin with:
Myung K. Shin United States
Angela Jeanes Australia
Jianmin Zhang China
Hitoki Hasegawa Japan
Yuanyuan Duan China
Lei Lei China
Yuejiao Huang China
Yanpan Gao China
Xue Liu relative to Myung K. Shin United States Myung K. Shin's profile →
Citations per field
00.5×5.2×
Myung K. Shin · 1×
Citations per year

Countries citing papers authored by Xue Liu

Since Specialization
Citations

This map shows the geographic impact of Xue Liu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xue Liu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xue Liu more than expected).

Fields of papers citing papers by Xue Liu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xue Liu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xue Liu. The network helps show where Xue Liu may publish in the future.

Co-authorship network of co-authors of Xue Liu

This figure shows the co-authorship network connecting the top 25 collaborators of Xue Liu. A scholar is included among the top collaborators of Xue Liu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xue Liu. Xue Liu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 0
2 3
3 3
4 34
5 1
6
Neutrophil Membrane‐Camouflaged Polyprodrug Nanomedicine for Inflammation Suppression in Ischemic Stroke Therapybreakdown →
66
7 3
8 0
9 17
10 7
11 5
12 1
13 5
14 6
15 75
16 15
17 7
18 182
19 20
20 71

About Xue Liu

Xue Liu is a scholar working on Cancer Research, Endocrinology and Immunology, having authored 37 papers that have together received 800 indexed citations. Recurring topics across this work include Extracellular vesicles in disease (11 papers), MicroRNA in disease regulation (8 papers) and interferon and immune responses (3 papers). The work is most often cited by research in Cancer Research (217 citations), Developmental Neuroscience (39 citations) and Molecular Biology (461 citations). Xue Liu has collaborated with scholars based in China, United States and United Kingdom. Frequent co-authors include Jing Kong, Tingjiao Liu, Xiaojie Li, Xuesong Yang, Fuyin Zhang, Yao Lu, Bo Sun, Dong‐Yan Jin, Yong Luo and Ke Cheng. Their work appears in journals such as Proceedings of the National Academy of Sciences, Advanced Materials and Journal of Neuroscience.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026